TerminatedPhase 2

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Stopped: Low recruitment

1 participantsStarted 2016-09-29

Plain-language summary

Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells. Currently there are no approved therapies for chronic GVHD in the USA, and patients with chroninc GVHD are treated with immunosuppressant drugs. T-lymphocytes (a type of white blood cells) are likely to play a role in the development of chronic GVHD. Due to the capacity of ponesimod to block the traffic of T-lymphocytes, ponesimod may be a new therapeutic approach to treat chroninc GVHD. The main objective of this study is to assess the effectiveness and safety of several doses of ponesimod in subjects with chronic GVHD who did not respond to standard available treatments.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent * Symptomatic moderate or severe chronic GVHD patients in need of a change of systemic immunosuppressant (IS) therapy * Women of child bearing potential must have a negative pregnancy test and use reliable methods of contraception Exclusion Criteria: * Clinically significant medical conditions including active or uncontrolled infections, new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes. * Karnofsky Performance Score \< 60. * Immunosuppressant therapies other than allowed background therapy * Anti-arrhythmic and heart rate lowering drugs. * Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

What they're measuring

Change in Peripheral Absolute Lymphocyte Count From Baseline to Week 4, 8 and 12

Timeframe: From baseline to Week 12

Trial details

NCT IDNCT02461134

SponsorActelion

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-03-02

Results submitted2018-03-02